{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:13:10Z","timestamp":1790392390671,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1136\/ijgc-2019-000609","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T04:55:10Z","timestamp":1567745710000},"page":"1389-1395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-5635","authenticated-orcid":false,"given":"Paul","family":"Buderath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt Werner","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Westerwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000609_bb0010","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2019-000609_bb0015","author":"Robert Koch-Institut","year":"2017"},{"key":"10.1136\/ijgc-2019-000609_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/annonc\/mdi104","article-title":"Prognostic factors in ovarian cancer: how close are we to a complete picture?","volume":"16","author":"Agarwal","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000609_bb0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000609_bb0030","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/0959-8049(94)E0125-N","article-title":"Response to second-line Weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen","volume":"30","author":"Bolis","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2019-000609_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000609_bb0040","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2019-000609_bb0045","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-2019-000609_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006412","article-title":"Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FOXP3 and TIA-1 as positive prognostic factors","volume":"4","author":"Milne","year":"2009","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2019-000609_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000609_bb0060","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2019-000609_bb0065","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1158\/1078-0432.CCR-05-1244","article-title":"The expression of the regulatory T cell-specific forkhead box transcription factor FOXP3 is associated with poor prognosis in ovarian cancer","volume":"11","author":"Wolf","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000609_bb0070","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1136\/ijgc-2019-000609_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1136\/ijgc-2019-000609_bb0080","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-000609_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"Pd-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000609_bb0090","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000609_bb0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1158\/2326-6066.CIR-13-0078","article-title":"Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer","volume":"1","author":"Brahmer","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/ijgc-2019-000609_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000609_bb0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ijgc-2019-000609_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/894704","article-title":"The immune response to tumors as a tool toward immunotherapy","volume":"2011","author":"Pandolfi","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1136\/ijgc-2019-000609_bb0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2019-000609_bb0120","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000609_bb0125","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"JCO"},{"key":"10.1136\/ijgc-2019-000609_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000609_bb0135","first-page":"432 p","author":"International Agency for Research on Cancer., and World Health Organization","year":"2003"},{"key":"10.1136\/ijgc-2019-000609_bb0140","first-page":"xx, 309 p","author":"International Union against Cancer","year":"2010"},{"key":"10.1136\/ijgc-2019-000609_bb0145","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2019-000609_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/1724600818770941","article-title":"Intratumoral immune cells expressing PD-1\/PD-L1 and their prognostic implications in cancer: a meta-analysis","author":"Kim","year":"2018","journal-title":"Int J Biol Markers"},{"key":"10.1136\/ijgc-2019-000609_bb0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-019-02528-6","article-title":"Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK\/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma","volume":"474","author":"Schmoeckel","year":"2019","journal-title":"Virchows Arch"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:24:04Z","timestamp":1753233844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24002974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1048891X24002974"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000609","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}